

# National Board of Examinations

|  |                           |
|--|---------------------------|
| <b>Question Paper Name :</b>                   | DrNB Endocrinology Paper1 |
| <b>Subject Name :</b>                          | DrNB Endocrinology Paper1 |
| <b>Creation Date :</b>                         | 2023-10-15 14:12:08       |
| <b>Duration :</b>                              | 180                       |
| <b>Share Answer Key With Delivery Engine :</b> | No                        |
| <b>Actual Answer Key :</b>                     | No                        |

## DrNB Endocrinology Paper1

|                                      |            |
|--------------------------------------|------------|
| <b>Group Number :</b>                | 1          |
| <b>Group Id :</b>                    | 3271872487 |
| <b>Group Maximum Duration :</b>      | 0          |
| <b>Group Minimum Duration :</b>      | 180        |
| <b>Show Attended Group? :</b>        | No         |
| <b>Edit Attended Group? :</b>        | No         |
| <b>Group Marks :</b>                 | 100        |
| <b>Is this Group for Examiner? :</b> | No         |
| <b>Examiner permission :</b>         | Cant View  |
| <b>Show Progress Bar? :</b>          | No         |

## DrNB Endocrinology Paper1

|                         |            |
|-------------------------|------------|
| <b>Section Id :</b>     | 3271872490 |
| <b>Section Number :</b> | 1          |
| <b>Section type :</b>   | Offline    |

|   |            |
|---|------------|
| <b>Mandatory or Optional :</b>                                      | Mandatory  |
| <b>Number of Questions to be attempted :</b>                        | 10         |
| <b>Section Marks :</b>  | 100        |
| <b>Enable Mark as Answered Mark for Review and Clear Response :</b> | Yes        |
| <b>Maximum Instruction Time :</b>                                   | 0          |
| <b>Sub-Section Number :</b>   | 1          |
| <b>Sub-Section Id :</b>   | 3271872494 |
| <b>Question Shuffling Allowed :</b>                                 | No         |
| <b>Is Section Default? :</b>  | null       |

**Question Number : 1 Question Id : 32718725103 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

**Please write your answers in the answer booklet within the allotted pages as follows:-**

| Question Number | Answer to be attempted within | Question Number | Answer to be attempted within |
|-----------------|-------------------------------|-----------------|-------------------------------|
| Q. 1            | Page 1-5                      | Q. 6            | Page 26-30                    |
| Q. 2            | Page 6-10                     | Q. 7            | Page 31-35                    |
| Q. 3            | Page 11-15                    | Q. 8            | Page 36-40                    |
| Q. 4            | Page 16-20                    | Q. 9            | Page 41-45                    |
| Q. 5            | Page 21-25                    | Q. 10           | Page 46-50                    |

1. Somatostatin analogues:

- Somatostatin receptors. [2]
- Available somatostatin analogues. [2]
- Diagnostic and therapeutic utility of somatostatin analogues. [6]

**Question Number : 2 Question Id : 32718725104 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- Transcription factors in pituitary development. [5]

b) Inherited pituitary deficiency due to transcription factor mutations. [5]

**Question Number : 3 Question Id : 32718725105 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

Pituitary irradiation:

- a) Indications. [2.5]
- b) Principles of stereotactic vs fractionated radiotherapy. [2.5]
- c) Remission rate and time to remission. [2.5]
- d) Side effects. [2.5]

**Question Number : 4 Question Id : 32718725106 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

A 42-year-old female, who was otherwise healthy previously presented with polyuria, polydipsia and weight loss. Her blood glucose levels were normal. How do you approach to this case?

- a) Relevant clinical history and examination. [3]
- b) Appropriate investigations and interpretation. [4]
- c) Diagnosis and management. [3]

**Question Number : 5 Question Id : 32718725107 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

Tyrosine kinase receptors - role in energy regulation:

- a) Ligands for tyrosine kinase receptor. [5]
- b) Regulation of glucose and lipid metabolism. [5]

**Question Number : 6 Question Id : 32718725108 Question Type : SUBJECTIVE Consider As**

**Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

Analytic validation:

- a) Pre-analytic parameters. [2.5]
- b) Intrinsic assay performance parameters. [2.5]
- c) Utilization parameters. [2.5]
- d) Interpretation parameters. [2.5]

**Question Number : 7 Question Id : 32718725109 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

A 10-year-old male child was brought by his parents with the complaints of headache, progressive diminution of vision and poor height gain for the past 1 year. Discuss the approach to the case:

- a) Relevant history. [2]
- b) Clinical examination. [2]
- c) Investigations. [2]
- d) Diagnosis and management. [4]

**Question Number : 8 Question Id : 32718725110 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Signaling pathways in the pathogenesis of obesity. [5]
- b) Recent advances in the pharmacotherapy of obesity. [5]

**Question Number : 9 Question Id : 32718725111 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Student's t-test. [5]

b) Confidence interval. [5]

**Question Number : 10 Question Id : 32718725112 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

Autoimmune Polyendocrine Syndrome (APS) type 1:

a) Various components/diseases of APS-1. [2.5]

b) Genetics. [2.5]

c) Clinical features. [2.5]

d) Diagnosis. [2.5]